$MGX

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Regulation FD Disclosure. Precision gene editing designed to deliver durable, curative medicines Corporate Presentation September 2026 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All

Reid Laurence purchased 20,000 shares of Metagenomi Therapeutics, Inc. (MGX) at an average of $1.17 ($1.17–$1.18) across 2 trades on 2026-09-09.

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

BlackRock-backed consortium including Abu Dhabi’s MGX and the Artificial Intelligence Infrastructure Partnership committed $5bn to expand Aligned Data Centres after closing its acquisition. Aligned was bought from Macquarie Asset Management and co-investors at a $40bn enterprise value. Aligned operates 51 campuses and 6.4GW capacity, with HQ in Dallas.

Reuters reports a BlackRock-backed consortium with Abu Dhabi’s MGX committed an additional $5 billion of growth capital to Aligned Data Centers after closing its $40 billion acquisition. The group, buying from Macquarie Asset Management, plans $30 billion of equity initially, potentially up to $100 billion including debt, to expand AI computing capacity.

Australia’s S&P/ASX 200 rose modestly, up 0.13% to 8,797.7 points by midday, after early gains. Brent crude climbed 3.1% to $91.07 on US-Iran escalation, lifting Viva Energy, Deep Yellow, Karoon, Woodside and Ampol. Semiconductor losses followed Moonshot’s Kimi K3 release; TSMC fell 7.3% and ASX tech/gold names also dropped.

MGX, an Abu Dhabi-backed AI investor, is exploring a multi-billion acquisition of Singapore-based data centre operator DayOne, three sources said. MGX has worked with an investment bank on the potential deal. DayOne plans a US IPO targeting a $20bn valuation, which MGX may not match; talks may not lead to a deal. DayOne is affiliated with GDS Holdings.

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001785279 false 0001785279 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09,

Metagenomi reported strong Q1 2026 financial results, with cash reserves of $140.2 million expected to fund operations through Q4 2027. The company advanced its MGX-001 hemophilia A program towards a late-2026 regulatory filing and 2027 trial initiation, while also showcasing in vivo proof-of-concept for its gene integration system and a compact CRISPR nuclease. Despite a decline in collaboration revenue, the company reduced R&D and G&A expenses, reinforcing its commitment to internally driven, potentially curative genetic treatments.

Metagenomi, Inc. ( NASDAQ:MGX ) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program. The data demonstrated curative factor VIII ( FVIII ) activity in non-human primates ( NHPs ) and informs a clinical dose regimen strategy.